People: Bausch Health Companies Inc (BHC.TO)

BHC.TO on Toronto Stock Exchange

23 Sep 2019
Change (% chg)

$-0.17 (-0.56%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

von Eschenbach, Andrew 

Dr. Andrew Charles von Eschenbach, M.D. is an Independent Director of the Company. Dr. von Eschenbach was appointed to the Board in October 2018. Since 2010, Dr. von Eschenbach has been the President of Samaritan Health Initiatives, Inc., a health care policy consultancy, and an Adjunct Professor at University of Texas MD Anderson Cancer Center. From September 2005 to January 2009, Dr. von Eschenbach served as Commissioner of the US Food and Drug Administration (the “FDA”). He was appointed Commissioner of the FDA after serving for four years as Director of the National Cancer Institute at the National Institutes of Health. As a researcher, clinician and administrator, Dr. von Eschenbach served for twenty-six years at the University of Texas MD Anderson Cancer Center as Chairman of Urology, Director of the Prostate Cancer Research Program and Executive Vice President and Chief Academic Officer. He earned a B.S. from St. Joseph’s University and a medical degree from Georgetown University School of Medicine in Washington, D.C., where he completed a residency in surgery and urology and then a fellowship in urologic oncology. From 2011 to 2013, Dr. von Eschenbach served on the boards of BioTime, Inc., a clinical-stage biotechnology company, and Elan Corporation Plc, a pharmaceutical company which was acquired by Perrigo in 2013. He also served on the board of Asterias Biotherapeutics, a biotechnology company focused on regenerative medicine, from 2013 to 2014.

Basic Compensation

Total Annual Compensation, USD 20,932
Restricted Stock Award, USD 128,025
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 148,957

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Joseph Papa


Paul Herendeen


Thomas Appio


Joseph Gordon


William Humphries


Mark McKenna

As Of  31 Dec 2018